PurposeBio is a synthetic biology platform that engineers therapeutics targeting fat absorption and digestion mechanisms, utilizing a non-systemic approach to address cardiometabolic diseases. Their technology aims to reduce adipocyte size by 50%, providing safe and effective treatment options for over 1 billion patients with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiometabolic diseases, affecting over a billion patients, require safe and effective treatments that address the body's fat absorption and digestion mechanisms. Current systemic approaches may have limitations in tolerability and specificity. There is a need for non-systemic therapeutics that can target fat absorption and digestion to reduce adipocyte size and improve patient outcomes.
Solution
Purpose Bio is developing a synthetic biology platform to engineer therapeutics that target the key mechanisms of fat absorption and digestion. Their non-systemic approach aims to reduce adipocyte size, offering a potentially safer and more tolerable treatment option for cardiometabolic diseases. The company leverages a library of intellectual property and a team of scientists to develop therapeutics designed to improve patient lives. Early proof-of-concept data indicates a 50% reduction in fat cell size with Purpose Bio's approach.
Target Audience
The primary target audience includes patients with cardiometabolic diseases and healthcare providers seeking safer and more effective treatment options.
Features
- Therapeutics target the body's fat absorption and digestion mechanisms
- Non-systemic approach for improved tolerability
- Aims to reduce adipocyte size
- Leverages a library of intellectual property